World Hepatitis Day 2021- Hep Can’t Wait!

World Hepatitis Day held on 28 July is an opportunity to step up national and international efforts on hepatitis.

Although preventative measures such as donor and blood screening have increased blood safety and have virtually removed the risk of transfusion-transmitted infections in Australia, chronic hepatitis remains a concern in the genetic haemoglobin disorder community in Australia due to past infection and internationally due to still inadequate blood safety measures.

This World Hepatitis Day, we support the global call to eliminate hepatitis especially for those with genetic haemoglobin disorders. 

Australia can’t wait to eliminate hepatitis!

Learn more at Australia’s World Hepatitis Day official website.

 

Hepatitis

Hepatitis B and hepatitis C are viruses that cause damage to your liver. They can be chronic, which means you could have them your whole life. Without treatment, they can lead to liver disease or liver cancer.

To see the latest statistics about hepatitis B and hepatitis C in Australia and why Australia can’t wait to eliminate hepatitis you can down load the World Hepatitis Day 2021 Factsheet using the button below.

Hepatitis B

In Australia, approximately 220,000 people are living with lifelong Hepatitis B and many are unaware they have the virus.

There is a safe and effective vaccine to protect you against getting hep B.

You can get treatment to manage chronic hepatitis B but not cure it.

Hepatitis C

In Australia, approximately 120,000 people are still living with chronic hepatitis C at the end of 2019 and many are unaware they have the virus or have not been fully diagnosed.

There is no vaccine to protect against hepatitis C, but there is an effective cure. The medicines known as direct-acting antivirals (or DAAs) are easy to take with as little as one tablet a day, no injections and most people experience few to no side effects.

Most people can get a prescription from their GP. They are low cost for people who have a Medicare Card.


Source: Hepatitis Australia

2021 Hepatitis Australia Factsheet

This document provides some useful statistics and information for World Hepatitis Day communications, including some new data not previously available in the public domain.

TASCA Newsletter (Winter 2021)

The latest TASCA newsletter is out now. 

Contents:

  • Light Up Australia
  • AGM Announcement
  • Raffle Winners
  • ITD2021
  • Thalassaemia International Federation Update
  • Who’s Inspiring Us?
  • A Tribute to Tim Vine 
  • What’s TASCA Been Up To?
  • TASCA 4 Kids Page

Want a hard copy? Let us know by sending a request through email.

You can also download a PDF here.

View previous newsletters here.

New TIF Resources: Thalassaemia Guidelines and COVID-19 Vaccination Guide

It’s Here: The 4th Edition of TIF Guidelines for The Management of TDT 

TIF, its Board of Directors and its International Scientific Advisory Board proudly present the 4th Edition of the Federation’s most prestigious and renowned publication, the TIF Guidelines for The Management of Transfusion- Dependent Thalassaemia (TDT).

Since 1999, when the very first edition was originally released as part of the Federation’s Educational Programme, the TIF Guidelines have been adopted and used extensively by academics, researchers and healthcare professionals all over the world as the only evidence-based reference text concerning the treatment of patients with TDT.

The newly launched edition includes brand new chapters on the recently approved modalities of patient treatment, the value of patient engagement at the decision-making level, the Reference Centres’ contribution to patient care, and much more.

We are confident that these Guidelines will offer once again valuable information to all allied physicians involved in the treatment of patients with this blood disorder and will consequently benefit the global thalassaemia community many times over. 

The June Update: TIF’s Guide on COVID-19 Vaccinations and Therapeutic Drugs 

As vaccination rates are slowing in the US and Europe, the spread of the Delta coronavirus variant causes growing concerns worldwide with health experts predicting the highly infectious strain to soon account for the majority of COVID-19 cases globally.

In our latest Guide on ‘COVID-19 Vaccinations and Therapeutic Drugs’, we have gathered the latest news, updates, and the information you need about: 

  • the current status of COVID-19 vaccinations in major countries and regions  
  • the clinical development and production of COVID-19 vaccines 
  • a breakdown of differences between the Pfizer, Moderna, AstraZeneca, and Johnson & Johnson COVID-19 vaccines 
  • the COVID-19 variants and the existing vaccines’ effectiveness 
  • the COVID-19 vaccines in Phase 3 clinical trials